Doshi, Jalpa A <br/><br/>
Trends and Factors Associated With Insurer Approval of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Prescriptions.  [electronic resource] 

 -  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research  02 2020 
 - 209-216 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1524-4733 
<br/><br/><label>Standard No.: </label>10.1016/j.jval.2019.08.011  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Anticholesteremic Agents--adverse effects<br/>Cross-Sectional Studies<br/>Databases, Factual<br/>Drug Costs<br/>Drug Prescriptions<br/>Eligibility Determination--economics<br/>Female<br/>Formularies as Topic<br/>Health Care Rationing--economics<br/>Health Services Accessibility--economics<br/>Humans<br/>Insurance Coverage--economics<br/>Insurance, Pharmaceutical Services--economics<br/>Male<br/>Medicare--economics<br/>Middle Aged<br/>PCSK9 Inhibitors<br/>Prior Authorization--economics<br/>Serine Proteinase Inhibitors--adverse effects<br/>Time Factors<br/>United States